ACE — Ascelia Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK71.37m
- SEK33.84m
Brief: Ascelia Pharma Q2 EPS at SEK -1.19
Brief: Ascelia Pharma: Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE
Brief: Ascelia Pharma Q1 Operating Loss Widens To SEK 36.7 Mln
Brief: Ascelia Pharma Announces Third Patent Covering Oncoral In USA
Brief: Ascelia Pharma Q4 Oper Loss Widens To SEK 52.2 Mln
Brief: Ascelia Pharma's Orviglance Data Shows Sparkle Study Can Be Completed With Fewer Patients
Brief: Ascelia Pharma Presents Results Of Orviglance Food Effect Study At RSNA 2022
Brief: Ascelia Pharma Q3 Operating Loss Narrows To SEK 29.6 Million
Brief: Ascelia Pharma Announces Successful Final Results
Brief: Ascelia Pharma Q2 Operating Loss At SEK 32.7 Mln
Brief: Ascelia Pharma Appoints Déspina Georgiadou Hedin As New CFO
Brief: Ascelia Pharma: Second US Patent For Oncoral Strengthens Coverage
Brief: Ascelia Pharma Q1 Operating Loss Narrows To SEK 32.6 Mln
Brief: Ascelia Pharma: Orviglance Image Enhancement Of Liver Is Not Reduced By Light Meal
Brief: CFO Kristian Borbos To Leave Ascelia Pharma
Brief: Ascelia Pharma Suspends Clinical Activities In Russia
Brief: Ascelia Pharma Q4 Operating Loss Widens To SEK 39.2 Mln
Brief: Ascelia Pharma Q3 Operating Loss Widens To SEK 32.7 Mln
Brief: Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology